{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T11:28:01Z","timestamp":1774870081832,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.ejphar.2018.02.007","type":"journal-article","created":{"date-parts":[[2018,2,9]],"date-time":"2018-02-09T18:17:12Z","timestamp":1518200232000},"page":"128-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney"],"prefix":"10.1016","volume":"824","author":[{"given":"Lodi C.W.","family":"Roksnoer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Estrellita","family":"Uijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren\u00e9","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid M.","family":"Garrelds","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.H.","family":"Jan Danser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.02.007_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1161\/01.HYP.20.1.89","article-title":"Role of neutral endopeptidase in the metabolism of endothelin","volume":"20","author":"Abassi","year":"1992","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1161\/CIRCHEARTFAILURE.111.962654","article-title":"Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial","volume":"4","author":"Anand","year":"2011","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ejphar.2018.02.007_bib3","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1161\/01.HYP.26.6.1160","article-title":"Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin","volume":"26","author":"Ando","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib4","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1007\/s00228-016-2072-7","article-title":"Effect of renal function on the pharmacokinetics of LCZ696 (sacubitril\/valsartan), an angiotensin receptor neprilysin inhibitor","volume":"72","author":"Ayalasomayajula","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.007_bib5","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/ki.1992.4","article-title":"Transgenic rats carrying the mouse renin gene--morphological characterization of a low-renin hypertension model","volume":"41","author":"Bachmann","year":"1992","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.02.007_bib6","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1161\/HYPERTENSIONAHA.113.02893","article-title":"Multiple ascending dose study with the new renin inhibitor VTP-27999: nephrocentric consequences of too much renin inhibition","volume":"63","author":"Balcarek","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib7","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1097\/00004872-200410000-00015","article-title":"L-S-nitrosothiols: endothelium-derived hyperpolarizing factors in porcine coronary arteries?","volume":"22","author":"Batenburg","year":"2004","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.02.007_bib8","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/cvr\/cvs016","article-title":"Angiotensin II-aldosterone interaction in human coronary microarteries involves GPR30, EGFR, and endothelial NO synthase","volume":"94","author":"Batenburg","year":"2012","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ejphar.2018.02.007_bib9","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1097\/HJH.0b013e32832bff54","article-title":"Light-induced vs. bradykinin-induced relaxation of coronary arteries: do S-nitrosothiols act as endothelium-derived hyperpolarizing factors?","volume":"27","author":"Batenburg","year":"2009","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.02.007_bib10","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/HJH.0b013e32835c1789","article-title":"The (pro)renin receptor blocker handle region peptide upregulates endothelium-derived contractile factors in aliskiren-treated diabetic transgenic (mREN2)27 rats","volume":"31","author":"Batenburg","year":"2013","journal-title":"J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.02.007_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/HYPERTENSIONAHA.117.09925","article-title":"Three-month endothelial human endothelin-1 overexpression causes blood pressure elevation and vascular and kidney injury","volume":"71","author":"Coelho","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib12","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/nrneph.2015.30","article-title":"Heart failure: new data do not SUPPORT triple RAAS blockade","volume":"11","author":"Danser","year":"2015","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejphar.2018.02.007_bib13","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1470320312455271","article-title":"Dual RAAS suppression: recent developments and implications in light of the\u00a0ALTITUDE study","volume":"13","author":"de Boer","year":"2012","journal-title":"J. Renin Angiotensin Aldosterone Syst."},{"key":"10.1016\/j.ejphar.2018.02.007_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0006-291X(91)90941-Y","article-title":"Vascular A10 cell membranes contain an endothelin metabolizing neutral endopeptidase","volume":"176","author":"Dickinson","year":"1991","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2018.02.007_bib15","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.97.23.2323","article-title":"Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo","volume":"97","author":"Ferro","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.02.007_bib16","doi-asserted-by":"crossref","first-page":"986","DOI":"10.3109\/00498254.2015.1014944","article-title":"Disposition and metabolism of [(14)C] Sacubitril\/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects","volume":"46","author":"Flarakos","year":"2016","journal-title":"Xenobiotica"},{"key":"10.1016\/j.ejphar.2018.02.007_bib17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.007_bib18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/1755-5922.12183","article-title":"Pharmacodynamic and pharmacokinetic profiles of sacubitril\/valsartan (LCZ696) in patients with heart failure and reduced ejection fraction","volume":"34","author":"Kobalava","year":"2016","journal-title":"Cardiovasc. Ther."},{"key":"10.1016\/j.ejphar.2018.02.007_bib19","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1161\/CIRCRESAHA.117.303776","article-title":"Contemporary approaches to modulating the nitric oxide-cGMP pathway in cardiovascular disease","volume":"120","author":"Kraehling","year":"2017","journal-title":"Circ. Res."},{"key":"10.1016\/j.ejphar.2018.02.007_bib20","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, Angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.02.007_bib21","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1161\/HYPERTENSIONAHA.114.04187","article-title":"Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study","volume":"64","author":"Lankhorst","year":"2014","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.02.007_bib23","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/344541a0","article-title":"Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene","volume":"344","author":"Mullins","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.02.007_bib24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ejphar.2018.02.007_bib25","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/sj.bjp.0705219","article-title":"Effects of the neutral endopeptidase inhibitor thiorphan on cardiovascular and renal function in cirrhotic rats","volume":"139","author":"Park","year":"2003","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.007_bib26","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1042\/CS20160197","article-title":"Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition versus AT1 receptor blockade alone","volume":"130","author":"Roksnoer","year":"2016","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejphar.2018.02.007_bib27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ki.2015.107","article-title":"Optimum AT1 receptor-neprilysin inhibition has superior cardioprotective effects compared with AT1 receptor receptor blockade alone in hypertensive rats","volume":"88","author":"Roksnoer","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/j.ejphar.2018.02.007_bib28","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1373\/clinchem.2015.239673","article-title":"Influence of glycosylation on diagnostic and prognostic accuracy of N-terminal pro-B-type natriuretic peptide in acute dyspnea: data from the Akershus Cardiac Examination 2 Study","volume":"61","author":"Rosjo","year":"2015","journal-title":"Clin. Chem."},{"key":"10.1016\/j.ejphar.2018.02.007_bib29","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejphar.2018.02.007_bib30","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0006-2952(97)00515-7","article-title":"In vitro enzymatic processing of radiolabelled big ET-1 in human kidney","volume":"55","author":"Russell","year":"1998","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.02.007_bib31","doi-asserted-by":"crossref","first-page":"e006617","DOI":"10.1161\/JAHA.117.006617","article-title":"Angiotensin II receptor-neprilysin inhibitor sacubitril\/valsartan improves endothelial dysfunction in spontaneously hypertensive rats","volume":"6","author":"Seki","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ejphar.2018.02.007_bib32","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0895-7061(96)00099-4","article-title":"Renal and antihypertensive effects of neutral endopeptidase inhibition in transgenic rats with an extra renin gene","volume":"9","author":"Stasch","year":"1996","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.ejphar.2018.02.007_bib33","first-page":"861","article-title":"Effects of metalloprotease inhibitors on the conversion of proendothelin-1 to endothelin-1","volume":"31","author":"Trapani","year":"1993","journal-title":"Biochem. Mol. Biol. Int."},{"key":"10.1016\/j.ejphar.2018.02.007_bib34","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11906-016-0694-x","article-title":"From ARB to ARNI in cardiovascular control","volume":"18","author":"Uijl","year":"2016","journal-title":"Curr. Hypertens. Rep."},{"key":"10.1016\/j.ejphar.2018.02.007_bib35","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1161\/HYPERTENSIONAHA.115.05267","article-title":"Association studies suggest a key role for endothelin-1 in the pathogenesis of preeclampsia and the accompanying renin-angiotensin-aldosterone system suppression","volume":"65","author":"Verdonk","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.ejphar.2018.02.007_bib36","doi-asserted-by":"crossref","first-page":"14150","DOI":"10.1016\/S0021-9258(18)77280-3","article-title":"The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase)","volume":"265","author":"Vijayaraghavan","year":"1990","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.02.007_bib37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jchf.2015.03.011","article-title":"Elevated plasma B-type natriuretic peptide concentrations directly inhibit circulating neprilysin activity in heart failure","volume":"3","author":"Vodovar","year":"2015","journal-title":"JACC Heart Fail."},{"key":"10.1016\/j.ejphar.2018.02.007_bib38","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/CIRCHEARTFAILURE.112.000289","article-title":"Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure","volume":"6","author":"von Lueder","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.ejphar.2018.02.007_bib39","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ. Heart Fail."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300876?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918300876?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,14]],"date-time":"2022-08-14T04:19:59Z","timestamp":1660450799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918300876"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":39,"alternative-id":["S0014299918300876"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.007","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neprilysin inhibition and endothelin-1 elevation: Focus on the kidney","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}